Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.80 |
| ▸ | INSR | P06213 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.63 |
| ▸ | LATS1 | O95835 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | LYN | P07948 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.63 |
| ▸ | MET | P08581 | 1/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.63 |
| ▸ | INSRR | P14616 | 1/20 | 0.63 |
| ▸ | FECH | P22830 | 1/20 | 0.63 |
| ▸ | MARK3 | P27448 | 1/20 | 0.63 |
| ▸ | FLT4 | P35916 | 1/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396469 | 0.90 | IGF1R (0.80) | IGF1RCYP3A4INSRKDRMAPK3 | |
| SCHEMBL10225308 | 0.89 | IGF1R (1.00) | IGF1RCYP3A4INSRKDRMAPK3 | |
| SCHEMBL19263995 | 0.88 | IGF1R (0.78) | IGF1RCYP3A4INSRKDRMAPK3 | |
| SCHEMBL1154828 | 0.87 | IGF1R (0.66) | IGF1RCYP3A4INSRKDRMAPK3 | |
| SCHEMBL26052888 | 0.87 | IGF1R (0.83) | IGF1RCYP3A4INSRKDRMAPK3 | |
| SCHEMBL13994500 | 0.86 | IGF1R (0.94) | IGF1RCYP3A4INSRKDRMAPK3 | |
| Bicarbonate SCHEMBL4070194 | 0.85 | IGF1R (0.88) | IGF1RCYP3A4INSRKDRMAPK3 | |
| Carbamic Acid SCHEMBL4066378 | 0.84 | IGF1R (0.86) | IGF1RCYP3A4INSRKDRMAPK3 | |
| SCHEMBL1154956 | 0.83 | IGF1R (0.83) | IGF1RCYP3A4INSRKDRMAPK3 | |
| SCHEMBL1155082 | 0.83 | IGF1R (0.83) | IGF1RCYP3A4INSRKDRMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | claimed |
| EP-2250173-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | claimed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | claimed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. | 2011-02-24 | — | — | US | disclosed |
| EP-2250173-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091939-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | OSI PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046144-A1 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS | IGF1R, IGFBP3, INSR | IGF1R 1/4885CYP3A4 265/4885INSR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.